The BRB Preclinical Repository
for distribution of cytokines, monoclonal antibodies,
reference standards, antisera and other reagents is currently closed.
On-line orders for recombineering reagents can still be placed on this website.
SHIPPING INFORMATION FOR RECOMBINEERING REAGENTS
Shipping costs are the responsibility of the recipient.
Once you have placed your order, you will be contacted to arrange payment of the
fee. Fed Ex, UPS or DHL account numbers or if required by recipient’s institution,
a PDF of shipping label(s) are accepted.
NOTE: Required NCI agreements for specific materials are obtained only following
the completion of an on-line request. Email and telephone requests are not accepted.
The BRB is developing clinical and non-clinical supplies of some of the immunomodulating
agents prioritized in the 2007 Immunotherapy Agent Workshop. Agents such as Ad-CCL21,
IL-7, IL-12, IL-15 and MPL will be made available to the community, through a variety
of standard mechanisms.
Limited amounts of the ch14.18 monoclonal antibody currently in Phase III clinical
trials for neuroblastoma are available for investigators interested in identifying
additional disease indications for this antibody. The antibody produced from SP2/0
hybridoma cells targets the disialoganglioside (GD2). Ch14.18 is suitable for use
in ADCC or other assays requiring a humanized antibody. A murine version of the
antibody (14.18G2a) is also available for immunohistochemistry studies. The 1A7 anti-idiotype
antibody that recognizes GD2 antibodies is also available.
For current development status and information on how to obtain one of these special
agents, please contact Dr. Karen Muszynski.